Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Geoffrey L. Uy, MD: Investigating Flotetuzumab in AML and MDS

December 30, 2021
Dr. Uy discusses preliminary results from a phase I trial of flotetuzumab, a CD123 x CD3 bispecific DART protein, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes, as well as the challenges of finding new targets in AML.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
Mid-July 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals